Cefixime: Clinical Overview
Cefixime is an oral third-generation cephalosporin indicated for uncomplicated urinary tract infections, otitis media, pharyngitis/tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea, with standard adult dosing of 400 mg once daily. 1
Indications
Cefixime is FDA-approved for treatment in adults and pediatric patients ≥6 months old for:
- Uncomplicated urinary tract infections (including complicated UTIs in outpatient settings when ESBL production is not a concern) 2, 1
- Otitis media 1
- Pharyngitis and tonsillitis 1
- Acute exacerbations of chronic bronchitis 1
- Uncomplicated gonorrhea (cervical/urethral) 1
The 2025 IDSA guidelines specifically list cefixime as an oral empiric option for complicated UTIs in patients suitable for outpatient management, though they note that oral beta-lactams may have inferior outcomes compared to fluoroquinolones or TMP-SMX 2.
Dosing Recommendations
Adults
- Standard dose: 400 mg once daily 3, 1
- Can be administered with or without food, though food delays absorption by approximately 0.8 hours 1
- For UTI step-down therapy: 400 mg once daily 2, 3
Pediatric Patients (≥6 months)
- 8 mg/kg/day 1
- Can be given as a single daily dose or divided into two doses 3
- Safety and efficacy in infants <6 months have not been established 1
Renal Impairment
Dose adjustment required when creatinine clearance <60 mL/min 1. Patients on dialysis should be monitored carefully 1.
Important Pharmacokinetic Considerations
- Oral absorption: 40-50% 2, 3
- Urinary excretion: 50% 2, 3
- Oral suspension produces 25-50% higher peak concentrations than tablets 1
- Tablets should NOT be substituted for oral suspension in otitis media treatment due to lack of bioequivalence 1
- The 400 mg capsule is bioequivalent to the 400 mg tablet under fasting conditions, but food reduces absorption by ~15% 1
Contraindications
Cefixime is absolutely contraindicated in patients with known allergy to cefixime or other cephalosporins 1.
Warnings and Precautions
Hypersensitivity Reactions
- Shock and fatalities have been reported 1
- Discontinue immediately if hypersensitivity reaction occurs 1
Clostridioides difficile-Associated Diarrhea
- Evaluate if diarrhea occurs during or after treatment 1
Drug Interactions
- Carbamazepine: Elevated levels reported with concomitant use 1
- Warfarin/anticoagulants: Increased prothrombin time with or without clinical bleeding 1
Laboratory Test Interferences
- False-positive urine ketones with nitroprusside tests 1
- False-positive urine glucose with Clinitest®, Benedict's, or Fehling's solution 1
- False-positive direct Coombs test 1
Adverse Effects
Most Common (from FDA label)
The most frequently reported adverse effects are gastrointestinal 1:
- Diarrhea (16%) - most common
- Nausea (7%)
- Loose stools (6%)
- Abdominal pain (3%)
- Dyspepsia (3%)
- Vomiting
Clinical Trial Data
- Gastrointestinal disturbances are usually mild to moderate, transient, and occur mostly in the first few days of treatment 4
- Once-daily 400 mg dosing showed higher incidence of GI adverse effects than 200 mg twice daily 5
- In a large post-marketing surveillance study of 9,568 patients, adverse events occurred in only 1.12% of adults and 1.92% of children 6
Serious Adverse Effects
Special Populations
Pregnancy
- Pregnancy Category B 1
- Should be used during pregnancy only if clearly needed 1
- Extremely low penetration into fetal tissues (<1% of dose) 8
Nursing Mothers
- Unknown if excreted in human milk 1
- Consider discontinuing nursing temporarily during treatment 1
- Breast milk penetration <1% of dose 8
Geriatric Use
- No dosage adjustment needed based on age alone 1
- Small pharmacokinetic differences detected but not clinically significant 1
Clinical Efficacy Context
Urinary Tract Infections
Cefixime demonstrates good efficacy in uncomplicated UTIs with comparable results to co-trimoxazole and amoxicillin 4, 5. However, the 2025 IDSA guidelines note that oral beta-lactams (including cefixime) may have inferior outcomes compared to fluoroquinolones or TMP-SMX for complicated UTIs 2.
Respiratory Tract Infections
Multiple trials established efficacy comparable to amoxicillin, cefaclor, and other comparators for lower respiratory tract infections 4, 7, 6.
Gonorrhea Treatment Limitation
Recent data shows cefixime 800 mg failed to achieve non-inferiority to ceftriaxone for gonorrhea treatment, particularly for pharyngeal infections 9. This represents an important limitation for this indication despite FDA approval.